• (PLX AI) – Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide.
  • • Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosing in humans
  • • Effects on several biomarkers suggest that clinically relevant exposures of dapiglutide were achieved in the study
  • • Zealand will be exploring several potential indications in gastrointestinal and metabolic diseases

Quelle: PLX AI